Readoutin 14d
Shanghai JMT-Bio Inc. — KN026
Phase 3 primary completion: A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Early or Locally Advanced HER2-positive Breast Cancer